A novel formulation of ketorolac tromethamine for intranasal administration: preclinical safety evaluation.
Ketorolac tromethamine is a potent analgesic and moderately effective anti-inflammatory drug approved for treatment of moderately severe acute pain as an intravenous/intramuscular injectable solution and an oral tablet. ROXRO PHARMA, Inc has developed an intranasal formulation, SPRIX, that delivers the drug with a similar pharmacokinetic profile to that obtained with intramuscular administration. Local tolerance and systemic toxicology studies were performed in rats and rabbits and showed that intranasal administration of SPRIX exhibits toxicity similar to that of other routes of administration and does not result in any adverse effects on the nasal passage and upper and lower respiratory system.
Boyer
Kelley C
KC
SciLucent, LLC, Herndon, VA, USA.
McDonald
Paddy
P
Zoetis
Tracey
T
D000281:Administration, Intranasal; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000473:pathology; D020911:Ketorolac Tromethamine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D008297:Male; D009666:Nose / Q000187:drug effects / Q000473:pathology; D011817:Rabbits; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018675:Toxicity Tests
D000894:Anti-Inflammatory Agents, Non-Steroidal; D020911:Ketorolac Tromethamine